We have explored the consequences of setting
ogy and consequences of erythropoietin intervention Iron protocol for study 1 points, rather than any other elements of the manageAnaemic patients (Hb <threshold) with a ferritin ment of renal anaemia. The treatment of iron deficiency <100 ng/ml (iron deficient) received iron saccharate (i.v. using a computer-based algorithm in a haemodialysis Fe) 100 mg/week for 8 weeks. If the ferritin remained population will be reported as part of another study.
<100 ng/ml a further 4-weeks dose of 100 mg/week was administered. For ferritin 100-250 ng/ml in anaemic patients and in ferritin ∏250 ng/ml with a 'normal' Hb (Hb Áthreshold), %HRC was assessed as a marker of functional iron deficiency. If the %HRC was Á5% (functionally iron Subjects and methods deficient) iron saccharate 50 mg/week for 4 weeks was given.
The initial values of ferritin and %HRC at which therapy Study 1. Therapeutic thresholds for Epo dose increments was prescribed and the evidence base for response according to %HRC are described in our previous study [6 ] . When All hospital and satellite haemodialysis patients were included the ferritin was >250 ng/ml or %HRC <5% (iron replete) regardless of co-morbidity. Monthly pre-dialysis blood intravenous iron was discontinued. results for Hb, ferritin, and percentage hypochromic red cells (%HRC ) were processed to provide recommendations for Study 2. Therapeutic ceilings for Epo dose decrements best therapy for the following month in terms of change to Epo dose or intravenous iron replacement. A clinician (DR) After an 8-month washout period at a unified threshold for monitored the recommendation of the algorithm and assessed intervention of 11.0 g/dl, a second randomization was perthe patient for hypertension, resistant iron deficiency, resist-formed. Patients were randomized to a reduction in Epo ant anaemia, and raised inflammatory markers each month. dose at Hb levels above 12.0 g/dl (group C ) or 13.0 g/dl The protocol was followed unless a specific clinical reason (group D) (the intervention ceilings). Patients in each group for deviation could be detected and recorded. The system were otherwise managed identically by the prevailing algowas designed to respond to signs of iron deficiency (absolute rithm. Study 2 was designed to investigate the effect of setting or functional ) with intravenous iron saccharate prior to any two different Hb ceilings for Epo dose decrement on the Hb increase in Epo dose. Once signs of iron deficiency had been outcome distribution and Epo expenditure. All hospital and corrected by criteria set for study 1 (vide infra), Epo doses satellite haemodialysis patients were included regardless of were increased (by 1000 IU/dose) if Hb values fell below co-morbidity. declared threshold levels. The choice of dose increments/ Epo dose decrements at the ceiling values were by decrements of 1000 IU (per dose administered ) was a prag-1000 IU/dose administered. If Hb values increased to above matic one. Epo doses were not increased if the patient was 15.5 g/dl at any time the Epo dose was halved as in study 1. hypertensive. Hypertension was defined as any pre-dialysis diastolic blood pressure Á100 mmHg in the preceding 14 Iron protocol for study 2 days. A maximum Epo dose was set at 300 IU/kg/week. Doses were reduced in a decremental fashion at a ceiling Hb A combination of low-dose maintenance therapy and incre-(14.0 g/dl; decrease Epo by 1000 IU/dose, 15.5 g/dl; halve mental replacement dosing was used for iron-replete patients Epo dose). All Epo was administered via the subcutaneous and those with signs of absolute/functional iron deficiency route.
respectively. Ferritin <100 ng/ml (absolute iron deficiency) Patients were randomized to intervention with an increase was treated with iron saccharate 50 mg thrice weekly. in Epo dose at Hb levels falling below 10.5 g/dl (group A) Treatment for ferritin 100-500 ng/ml depended upon evidor 11.5 g/dl (group B) (the intervention thresholds) and ence of functional iron deficiency as determined by %HRC. followed for 6 months. Patients in each group were otherwise For %HRC ∏2 (iron replete), iron saccharate 50 mg/week managed identically by the prevailing algorithm. The baseline was administered, for %HRC >2-<5 (iron replete), 50 mg characteristics for the population at entry into the study are twice weekly, and for %HRC Á5 (functional iron deficiency), given in Table 1 . Transfusion criteria were the same for both iron saccharate 50 mg thrice weekly was administered. For groups: transfuse for Hb<6.0 g/dl or for symptomatic ferritin above 500 ng/ml (iron replete) intravenous iron therapy was withheld. anaemia. 
Statistics
Statistical significance was tested using the paired samples ttest+, independent samples t-test++ for equality of the means (P quoted for 'equal variances not assumed'), the variance ratio test## (F test) for parametric data, the Wilcoxon signed-rank test*, the Mann-Whitney U-test** for non-parametric data, and the Chi-Squared test#.
Results

Study 1. Thresholds
A haemodialysis population of 236 patients at entry was followed for 6 months. Thirty-five patients did not plantation (10), conversion to continuous ambulatory peritoneal dialysis (CAPD) (7), and transfer to another hospital (1) . The data showed no significant differences between the two groups ( Table 2) . Epo doses were not increased on 17 occasions when the patient was hypertensive. Intolerance to treatment occurred in two patients. One developed vomiting shortly after receiving i.v. iron saccharate and was converted to iron dextran. The second developed migraine on Epo 6000 IU/week and the dose was set at a maximum of 3000 IU/week (71 IU/kg/week).
The population mean Hb increased from 10.2 g/dl to 11.4 g/dl (SD 1.8) (P<0.001+). Transfusion decreased from 47 units in 236 patients in month 1 to 23 units in 201 patients in month 6. Transfusion did not differ between groups A and B in any month**. The proportion of patients with an Hb Á10.0 g/dl increased from 50 to 80% at 6 months. A developing difference in Hb outcome between the two randomized groups was significant from the third month (P= 0.001++) (Figures 1-3) . The mean Hb differed in the two groups at 6 months by 0.6 g/dl (P=0.04++) having increased from baseline in both: group A, Hb 10.0 to 11.2 g/dl (SD 1.7 g/dl ); group B, Hb 10.2 to 11.7 g/dl (SD 2.1 g/dl ). The outcome mean Hb was above the respective threshold for intervention in both groups and the medians were 0.9 g/dl apart, close to the difference between the threshold values ( Figure 3 ). There was no difference in the outcomes for ferritin or %HRC between the groups A and B** ( Table 3) . There was an increase in Epo dose in both groups during study 1 (group A, median 88 IU/kg/week (6000 IU/week) (IQR, 47-124) to 134 (9000 IU/week) (IQR 88-223) (P<0.001*) and group B, 72 (3000 IU/week) (IQR, 39-119) to 141 (9000 IU/week) (IQR, 
Study 2. Ceilings
The unselected haemodialysis population of 211 patients at entry was followed for 8 months (vide infra).
There was no significant difference between the baseline characteristics of the two groups ( Table 4) . Thirty-three patients did not complete 8 months of study: due to death (18), transplantation (7), conversion to CAPD (1), transfer to another hospital (6), recovery of renal function (1). There was no significant difference for failure to complete the study between the two groups ( Table 5 ).
The population Hb increased from a mean of 11.4 g/dl (SD 1.8 g/dl ) to 11.6 g/dl (SD 1.9) (P= 0.02+). The ferritin increased from a median of 406 mg/ml (IQR, 259-491) to 542 mg/ml (IQR, period did not differ between Groups-C (17 of 103 patients) and D (23 of 118 patients)#. The haemoglobin outcomes developed a difference from 7 months (P= percentage of Hb values <10.0 g/dl were 13.5 and 0.002++) and at 8 months the mean Hb outcome in 15.5% respectively. Importantly, the standard deviation group C (11.5 g/dl, SD 1.4) was lower than group D for Hb values was less for group C, with a standard (12.2, SD 2.1) (P=0.001++) (Figures 4-6 ). The deviation of 1.37 g/dl vs 2.07 g/dl for group D (P<0.001##). There was no difference in measured Table 5 . Reasons for not completing study 2 iron parameters between the two groups during the study ( Table 6 ).
Group C Group D P#
There was a decrease in Epo dose in both groups during study 2 (group C, 104 ( IQR, 45-200) to 0.6 g/dl (medians separated by 0.9 g/dl, and approximately 0.5 g/dl above the threshold value). Despite a difference in the outcome Hbs in groups A and B there were no differences in Epo dose, ferritin, or %HRC between the two groups. There were very few interventions at the ceiling values during this 6-month period, suggesting a low risk of toxicity secondary to polycythaemia. The results did not depend on any prospective 'target' values, being simply the outcome of the algorithm applied at the two threshold values.
After study 1 was completed, the two groups were unified at an intervention threshold of 11.0 g/dl. With the subsequent mean predicted as 11.5 g/dl and a SD of~1.7 g/dl, this system should have achieved~85% on haemodialysis.
The algorithm of monthly Epo dose adjustments and i.v. iron saccharate supplements evolved in response to the high Epo requirements in study 1 and audit of the iron parameters resulting from the declared iron protocol during that period of study. In response to the earlier outcomes, persistent iron deficiency was subsequently managed with incremental iron dosing (up to 50 mg iron saccharate i.v. three times weekly) and iron-replete patients received maintenance iron (50 mg/week) to prevent the development of iron deficiency [8] . Because of these changes the prevalence of iron deficiency decreased by the time the second study was undertaken. This was demonstrated by the lower erythropoietin doses necessary to maintain the same Hb outcome during study 2 as at the end of study 1. However, all the patients randomized into each treat- (with respect to iron supplements). The higher Epo requirements in study 1 are likely to have been second-
Discussion
ary to a combination of attainment (increasing haemoglobins from lower levels to above a minimum standard ) and the less aggressive iron replacement The management system produced a dramatic than in study 2. There is no reason to believe that the improvement in the population Hb profile over 6 prevailing iron protocol influenced the results of the months in study 1 through incremental use of Epo. randomized studies. The 1 g/dl difference in the set threshold values (for The consequence of managing renal anaemia with increments in Epo dosing) in the two groups led to two stable Hb distributions, with means separated by erythropoietin and iron is always a distribution of Hb Table 6 . Ferritin and %HRC outcomes by ceiling group in study 2 (months 0-8). No significant difference between groups C and D apart from month 5 (HRC (P=0.02**) and ferritin (P=0.04**))
Month
Ferritin (ng/ml ) (median and IQR) %HRC (median and IQR) values for any dialysis patient cohort. Such distribu-further discussion. We suggest that the differences may be explained by the increased frequency of Epo dose tions are typically Gaussian in character and have outcome SDs that are similar in most units across the interventions made in groups B and C (Figures 7, 8) .
The number of Epo dose interventions are dependent UK. The UK Renal Registry data [9] for example suggested the possibility of determining in advance the on the level at which the threshold/ceiling is set relative to the population Hb distribution at that time. For mean Hb necessary to achieve defined standard values (e.g. a mean of 11.5 g/dl for 85% Á10.0 g/dl ). Similar instance, in group B, with a threshold set at 11.5 g/dl, a larger proportion of the population had values that predictions can be made from cross-sectional and longitudinal data [10, 11] . The latest guidelines from fell below this threshold at the beginning of the study than for the threshold set at 10.5 g/dl. This hypothesis, the European Renal Association [3] (Preface 1.3 and Guideline 5A) acknowledge that the population mean based on the proportion of interventions in Epo dose, might also explain why, with a greater frequency of value must be significantly higher than the minimum standard in order to achieve distributions compliant interventions occurring in study 1 (with initially the majority of patients' values <11.0 g/dl ), there was a with that standard, but no formal methods are currently available to manipulate the distributions separation in the two groups by month 3. However, in study 2 the proportion of each group's Hb results that predictably.
The studies in this paper were designed to explore were above the ceiling values (resulting in an Epo dose intervention) was smaller and the Hb distributions did the consequences of erythropoietin intervention at two lower threshold and two upper ceiling Hb values, in not separate significantly until 7 months of study.
These studies in the St James's renal population an iron-replete dialysis population. The principle was less concerned with target values being used as 'aiming points', than with the Hb values at which Epo doses should be increased or decreased in order to shape the outcome distribution. Because of inertia in the declining values and momentum in the values that are rising there is a need to choose the points at which interventions effectively throw the Hb back towards the middle of the distribution. Intervention on declining values must clearly precede transgression of 10 g/dl ( UK Renal Association Standard ) in order to maintain the distribution. Likewise the momentum of the erythropoietic tissue, under Epo/iron stimulation, means that a relatively low ceiling must be chosen to limit overshoot into higher values. These are pre-emptive (pro-active) rather than reactive interventions; a clinical response is elicited before marginal values are ever reached.
Our studies demonstrate the ability of a formal management system to produce different outcome distributions by using threshold and ceiling values for Epo dose intervention. The threshold study (study 1) study 1, months 1-6. produced two outcome distributions with mean values separated by just over 0.5 g/dl from 3-6 months. The ceiling study (study 2) again separated the outcome distributions through the use of a ceiling value 1 g/dl and 2 g/dl greater than the then unified threshold value of 11.0 g/dl (with outcome means approximating to the midpoints between threshold and ceiling values in each group). The utilization of the lower ceiling value, with the same threshold at 11.0 g/dl, decreased the dispersion (SD) of the 12 g/dl-ceiling group compared to the 13.0 g/dl ceiling group. The ability to reduce the spread of outcome values is important in regard to both safety and cost-effectiveness. To narrow the distributions further will require the investigation of differential Epo dosing and frequency. Methods based on standard algorithms will allow this further study, as well as, for example, examining the timing interval for monitoring and intervention.
The different Hb outcome for groups A and B, and groups C and D respectively, despite comparable values for erythropoietin doses and iron parameters, requires
